CSAAI 2026 Educational Meeting: A Midsummer Night’s Wheeze

Huntington Beach, CA US
June 27, 2026 to June 28, 2026

It is an exciting time in the field of allergy and immunology.  This CME/CE program is designed to allow attendees to continue exploring the field.  Covered topics include Immune Deficiency, SCID, Asthma, Food Allergy, Eosinophilic Conditions and more!

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the California Society of Allergy, Asthma & Immunology (CSAAI).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 6.75 contact hours.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity learners should be able to…

1. Appraise current and emerging therapies, including oral and intralymphatic immunotherapy, in terms of safety, adherence, and long-term outcomes compared to strict avoidance.

2. Apply epidemiological insights and age-linked patterns of food allergy to guide individualized patient management across the life course.

3. Consolidate evidence on the identification and management of uncontrolled and severe asthma, incorporating phenotype, endotype, and biomarker assessment to guide individualized treatment.

4. Review the treatments used to treat primary Immunodeficiency

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN
Course opens: 
06/27/2026
Course expires: 
12/31/2026
Event starts: 
06/27/2026 - 12:00pm CDT
Event ends: 
06/28/2026 - 11:30am CDT
Rating: 
0

CSAAI 2026 Annual Meeting - A Midsummer's Night Wheeze
Program Agenda

All Education Sessions to be held in Huntington South
Exhibits and Coffee Breaks to be held in Huntington North

SATURDAY, JUNE 27

8:00 am-2:15 pm Registration

8:30-9:30 am Exhibits & Continental Breakfast

9:35-9:50 am Welcome & Overview , Raffi Tachdjian, MD, MPH, CSAAI President

9:50-10:40 am Fresh Air: What’s New in Moderate to Severe Asthma / Q&A, Praveen Akuthota, MD

Saturday Practice Management Symposium featuring Jennifer Kuehn, CPC
brought to you by California Society of Allergy, Asthma and Immunology and the
American College of Allergy, Asthma and Immunology

10:40-11:30 am 2026 Coding Update / Q&A, Jennifer Kuehn, CPC           

11:30 am-12:40 pm Lunch Break and Exhibits

12:40-1:30 pm Updates in Anaphylaxis Diagnosis and Management / Q&A, Julie Wang, MD

1:30-2:20 pm Primary Immunodeficiency Primer Update / Q&A, Ramsay Fuleihan, MD

2:20 pm Adjourn


SUNDAY, JUNE 28

7:00-7:50 am Continental Breakfast & Exhibits

7:50-8:00 am Overview, Javed Sheikh, MD, CSAAI Program Director

8:00-8:50 am Newborn Screening for SCID and other Immunodeficiency Disorders / Q&A, Ramsay Fuleihan, MD

8:50-9:40 am Eosinophilic Lung Diseases / Q&A, Praveen Akuthota, MD

9:40-10:20 am Coffee Break & Exhibits

10:20-11:10 am The Latest in Treatment Options for Food Allergy / Q&A, Julie Wang, MD

11:10-11:20 am Closing Remarks, Raffi Tachdjian, MD, MPH, CSAAI President 

11:20 am Adjourn
 

Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA 92648
United States

All relevant financial relationships with ineligible companies have been mitigated.

Praveen Akuthota, MD – Speaker
Consultant: AstraZeneca, Biopharma, Gilead, Sanofi
Researcher: 4D Molecular Therapeutics, AstraZeneca, Recode, Sanofi

Matthew Bowdish, MD – Planner
Advisor, Researcher, Speaker: GSK

Ramsay Fuleihan, MD – Speaker
Speaker: Grifols

Sonal Patel, MD – Planner
Speaker: Regeneron, Sanofi

Raffi Tachdjian, MD, MPH – Planner, Moderator
Advisor: Astria, Biocryst, CSL Behring, Kalvista, Pharming, Pharvaris, Takeda
Independent contractor: Astria, Biocryst, CSL Behring, Ionis, Kalvista, Pharing, Pharvaris, Takeda
Speaker: ARS, AstraZeneca, Biocryst, CSL Behring, Grifols, GSK, Lilly, Novartis, Pharming, Regeneron/Sanofi, Takeda

Julie Wang, MD – Speaker
Independent contractor: DBV Technologies, Siolta

 

The following have no relevant financial relationships with ineligible companies to disclose:

Karol Anderson – Planner
Jennifer Kuehn, CPC – Speaker
Myngoc Nguyen, MD – Planner
Javed Sheikh, MD – Planner, Moderator
Suzanne Teuber, MD – Planner

Available Credit

  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN
Please login or create an account to take this course.